US2023001007A1PendingUtilityA1

Glycan-Interacting Compounds and Methods of Use

65
Assignee: SEAGEN INCPriority: Mar 3, 2017Filed: Jan 4, 2022Published: Jan 5, 2023
Est. expiryMar 3, 2037(~10.6 yrs left)· nominal 20-yr term from priority
Inventors:Daniel T. DransfieldJillian M. PrendergastDavid A. Eavarone
A61K 33/243A61K 9/0019A61K 31/44A61K 31/4745A61K 47/6851A61K 2039/505A61K 47/6889A61K 31/7068A61K 45/06A61K 2039/545C07K 16/3076A61K 39/3955C07K 2317/92A61K 38/08A61K 31/519A61K 47/6817C07K 2317/24A61K 31/506A61P 35/00A61K 31/337C07K 16/2896A61K 38/17C07K 2317/73A61K 47/6949A61K 31/513C07K 2317/734C07K 2317/732C07K 16/30
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.

Claims

exact text as granted — not AI-modified
1 . A method of treating cancer in a subject comprising administering an antibody, wherein said antibody is administered at a dose of from about 1 mg/kg to about 10 mg/kg, wherein said antibody has a terminal half-life of from about 50 hours to about 200 hours, and wherein said antibody binds sialyl Tn antigen (STn). 
     
     
         2 - 58 . (canceled)

Join the waitlist — get patent alerts

Track US2023001007A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.